BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Academy of Nutritional Medicine - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Academy of Nutritional Medicine
X-ORIGINAL-URL:https://aonm.org
X-WR-CALDESC:Events for Academy of Nutritional Medicine
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20251202T190000
DTEND;TZID=Europe/London:20251202T200000
DTSTAMP:20260518T123045
CREATED:20251029T111122Z
LAST-MODIFIED:20251029T170346Z
UID:43473-1764702000-1764705600@aonm.org
SUMMARY:Evaluation of The Clinical Potential in Prostate Cancer Using Maintrac®
DESCRIPTION:Evaluation of The Clinical Potential in Prostate Cancer Using Maintrac® \nExploring the use of circulating epithelial tumour cell tracking (CETCs) to inform personalised and integrative approaches in cancer support \n*** \nDESCRIPTION \nProstate cancer remains the most common cancer among men\, with risk increasing significantly with age. Many cases involve slow-growing\, less aggressive tumours that can develop slowly over a period of many years. To help avoid overtreatment in these low-risk patients\, “active monitoring” and “watch-and-wait” approaches are often adopted\, allowing for careful observation over time. \nFor practitioners supporting clients with a diagnosis of prostate cancer\, gaining reliable insights into tumour behaviour without invasive procedures can be invaluable. Maintrac®\, a liquid biopsy method\, offers a new dimension of understanding\, enabling tumour activity to be assessed directly without the need for invasive interventions or imaging. In more advanced cases\, Stemtrac® can also be used to track circulating stem cells\, offering additional information on tumour cell behaviour. \nIn this upcoming webinar\, Professor Katharina Pachmann\, a pioneer in the field of liquid biopsy and circulating tumour cell (CTC) analysis\, will present how Maintrac® and Stemtrac® technologies are transforming the monitoring and management of prostate cancer\, including how effective therapeutic approaches are likely to be. She will also present their latest scientific study exploring the role of Maintrac® during radiotherapy\, and how these innovative methods can contribute to optimising therapy decisions. \nProfessor Katharina Pachmann will also discuss the analysis of key therapy-relevant biomarkers on circulating tumour cells\, including Prostate-Specific Antigen (PSA)\, Prostate-Specific Membrane Antigen (PSMA)\, the Androgen Receptor (AR)\, and B7-H3. \n*** \nABOUT THE SPEAKER \nProfessor Dr. med. Katharina Pachmann runs the Maintrac laboratory in Bayreuth\, Germany\, together with Dr. Ulrich Pachmann and a team of 45. As both a medical doctor and research scientist\, she has been conducting studies in this field and refining related techniques for over two decades\, and has authored over a hundred peer-reviewed scientific publications on the technique.
URL:https://aonm.org/event/evaluation-of-the-clinical-potential-in-prostate-cancer-using-maintrac/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://aonm.org/wp-content/uploads/2025/10/Maintrac-banner-v2.png
ORGANIZER;CN="Academy of Nutritional Medicine (AONM)":MAILTO:info@aonm.org
END:VEVENT
END:VCALENDAR